My expertise is in cell culture, more specifically in hybridoma generation and monoclonal antibody technologies. I obtained my Ph.D. in Experimental Pathology and Molecular Biology from Albany Medical College in 1985. My thesis project involved kidney disease related to alterations in fibronectin composition of the glomerular basement membrane.

My third and final post-doc position is what brought me to the laboratory of Dr. Martin Dorf at HMS Dept. of Pathology and my association with Vijay Kuchroo. The research initially involved working at identifying suppressor T cells and an underground project delving into the patho-etiology of Multiple Sclerosis. This is where PLP re-entered the picture. Vijay and I generated a panel of PLP reactive T cell hybridomas, epitope mapped them and used them to explore MS in an animal model known as Experimental Autoimmune Encephalomyelitis (EAE).

I spent 3 years working as a Scientist (and later Principle Investigator) for the Repligen Corporation in Cambridge , MA directing their Hybridoma Facility and developing reagents for the B7-CD28 Costimulation projects. One arm of this work involved immune suppression for controlling Graft vs. Host disease and autoimmune diseases. The other arm of the project looked at immune activation of T cells to control or irradicate tumor growth.

Issues in the Biotech industry lead to down-sizing at Repligen and my move to the Dana-Farber Cancer Institute to work for Lee Nadler and Jim Griffin to set up a Hybridoma Core Facility that would generate hybridomas and monoclonal antibodies for the department and later the Institute and Harvard Medical Area Community.

After 7 years at DFCI, I went back to the private sector to accept a position at Millennium Pharmaceuticals, Inc. as a Senior Scientist, where I continue to generate hybridomas as bio-therapeutics and reagent for supporting clinical trials of novel drug candidates.

Vijay and I have worked together and collaborated on many projects over the last 13 years. I look forward to continuing our projects together and generating many new and exciting monoclonal antibodies.